Extranodal NHLs can arise from a variety of anatomical districts. Participation is open to worldwide institutions.
For further information about the clinical trials, please contact us.
Ongoing Trials
- IELSG50
IELSG50 Pembrolizumab and radiotherapy for previously untreated patients with
limited-stage NK/T cell lymphoma who are not eligible for chemotherapyParticipants required: 30 Investigator responsible(s): S. Luminari and W. Zhao Objective(s): The primary objective of the IELSG50 trial is to test the efficacy of concurrent
RT-Pembrolizumab in patients with limited-stage high-risk NK/T cell lymphoma
who are not eligible or refuse to receive chemotherapy. - IELSG49
IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) Participants required: 24 Investigator responsible(s): A. Stathis, D. Rossi, E. Zucca Objective(s): The primary objective of the IELSG49 trial is to determine the efficacy of tafasitamab in combination with acalabrutinib in patients with relapsed or refractory MZL. - IELSG47 Study
IELSG47 MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas Participants required: 175 (130 patients with EMZL + 30 SMZL and 15 NMZL) Investigator responsible(s): C.Thieblemont, A. Conconi Objective(s): Aim of the study is to assess the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to explore its activity in SMZL and NMZL as exploratory subset. - IELSG46 Study
IELSG46 Integrated molecular and clinical profiling to optimize outcome prediction in Splenic Marginal Zone Lymphoma Participants required: Biological samples of at least 300 subjects Investigator responsible(s): D. Rossi Objective(s): To develop and validate an integrated clinic-molecular model for an accurate survival prognostication of newly diagnosed SMZL. - IELSG45 Study
IELSG45 Randomized phase II trial on fitness- and comorbidity- tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma (FIORELLA Trial) Participants required: 208 Investigator responsible(s): A. Ferreri Objective(s): Aim of the study is to assess the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to explore its activity in SMZL and NMZL as exploratory subset.The primary objective of this randomized phase II trial is to compare the efficacy of a new maintenance treatment consisting of oral lenalidomide with the oral procarbazine maintenance currently in use, in elderly (≥70 years) patients with newly diagnosed PCNSL eligible to receive HD-MTX-based induction chemo-immunotherapy. Aim of the study is to assess the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to explore its activity in SMZL and NMZL as exploratory subset. - IELSG44
IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s): S. Luminari, C. Thieblemont, E. Zucca Objective(s): The IELSG44 PIMENTO study is a multicenter retrospective analysis that will assess the role of PET for the staging and for the assessment of response and outcome prediction in Marginal Zone Lymphoma (MZL).
Trials with enrolment completed – Follow-up ongoing
| IELSG43 | High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma – randomized phase III trial (MATRix) |
| Participants required: | 342 (enrolment completed) |
| Investigator(s) responsible: | G. Illerhaus, A. Ferreri |
| Objective(s): | To compare the efficacy (in terms of progression-free survival) of two consolidation policies: high-dose chemotherapy followed by autologous stem-cell transplantation and chemotherapy at conventional doses (with a regimen specifically developed for CNS lymphoma). |
| IELSG42 | An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by autologous stem cell transplant, in patients with systemic B-cell lymphoma with central nervous system involvement at diagnosis or relapse (MARIETTA regimen) |
| Participants required: | 76 (enrolment completed) |
| Investigator(s) responsible: | A. Ferreri, E. Zucca, K. Cwynarski, G. Illerhaus, A. López-Guillermo, T. Siegal/O. Bairey, J. Bromberg |
| Objective(s): | To evaluate the efficacy and feasibility of a new sequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed by R-ICE regimen, and by high-dose chemotherapy supported by ASCT. |
| IELSG40 | A phase II trial addressing feasibility and activity of clarithromycin + lenalidomide combination: a full oral treatment for patients with relapsed/refractory mucosa-associated lymphoid tissue (malt) lymphoma (CLEO trial) |
| Participants required: | 62 (patients enrolled: 44 – enrolment discontinued per protocol, after the interim analysis) |
| Investigator(s) responsible: | A. Ferreri, M. Raderer |
| Objective(s): | To assess the overall response rate (complete and partial responses) of the combination treatment of clarithromycin and lenalidomide in patients with MALT lymphoma, refractory or relapsing after radiotherapy and/or chemotherapy and/or immunotherapy. |
| IELSG39 | International prospective phase 2 trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycycline followed by eradication monitoring and antibiotic re-treatment at infection re-occurrence in patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL) |
| Participants required: | 44 (enrolment completed) |
| Investigator(s) responsible: | A. Ferreri, E. Zucca, S. Govi |
| Objective(s): | To establish in a prospective, multicentre phase 2 trial, the efficacy of an upfront targeted therapy consisting of Cp-eradicating therapy with prolonged administration of doxycycline followed by eradication monitoring and antibiotic re-treatment at infection re-occurrence in patients with newly diagnosed OAMZL. |
| IELSG38 | A phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with extranodal marginal zone B-cell lymphoma of Mucosa Associated Lymphoid Tissue (MALT lymphoma) |
| Participants required: | 112 (enrolment completed) |
| Investigator(s) responsible: | A. Stathis, S. Luminari, L. Baldini, C. Thieblemont, R. Gressin, E. Zucca) |
| Objective(s): | to assess the therapeutic safety and activity of the combination of Chlorambucil and Rituximab given for 6 months, followed by 2 years maintenance treatment with subcutaneous Rituximab alone in MALT lymphomas. |
| IELSG37 | A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) |
| Participants required: | 540 (enrolment completed) |
| Investigator(s) responsible: | M. Martelli, A.J. Davies, M. Gospodarowicz, E. Zucca |
| Objective(s): | To evaluate the possibility to spare the radiotherapy in PMBCL patients, who have become “PET-negative” after a combined R-chemotherapy. |
| IELSG32 | Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed primary CNS lymphoma |
| Participants required: | 227(enrolment completed) |
| Investigator(s) responsible: | A. Ferreri, G. Illerhaus |
| Objective(s): | Primary objective of the first randomization is to establish the activity of three different chemotherapy combinations with high-dose methotrexate (HD-MTX) + high-dose cytarabine (HD-araC), HD-MTX + HDaraC + rituximab and HD-MTX + HD-araC + rituximab + thiotepa in patients with newly diagnosed PCNSL. At second randomization is to establish the efficacy of two consolidation strategies: conventional whole brain radiotherapy (WBRT) vs. high-dose chemotherapy supported by autologous stem cell transplantation (HDC + ASCT) in patients with newly diagnosed PCNSL. |
| IELSG30 | A phase II study of R-CHOP with intensive CNS prophylaxis and scrotal irradiation in patients with primary testicular diffuse large B-cell lymphoma |
| Participants required: | 54 (enrolment completed) |
| Investigator(s) responsible: | U. Vitolo, E. Zucca |
| Objective(s): | To assess the feasibility, activity and safety of a therapeutic program in which patients with testicular large cell lymphoma receive state-of-the-art chemoimmunotherapy (R-CHOP regimen) plus both intrathecal (with liposomal cytarabine) and systemic CNS prophylaxis (with intermediate-dose methotrexate), followed by locoregional radiotherapy. |
Closed Trials
| IELSG41 | A retrospective survey of extranodal marginal zone lymphoma of mucosa-associate lymphoid tissue of salivary glands. |
| Investigator(s) responsible: | G. Nowakowsky |
| Description: | A retrospective survey of extranodal marginal zone lymphoma of mucosa-associate lymphoid tissue of salivary glands. |
| IELSG36 | IELSG36 |
| Participants required: | 78 (enrolment completed) |
| Investigator(s) responsible: | E. Iannitto, C. Thieblemont, C. Montalban |
| Objective(s): | To evaluate the safety and the efficacy of R-Bendamustine in symptomatic patients with Splenic Marginal Zone Lymphoma not eligible or not willing to undergo splenectomy. |
| IELSG35 | A retrospective international study of primary extranodal lymphoma of female genital tract |
| Investigator(s) responsible: | G. Martinelli, G. Ryan |
| Description: | This retrospective analysis aims to provide an overview on this rare neoplasm to better understand clinical and histological characteristics and define diagnostic and treatment modalities, response rate and prognosis. |
| IELSG34 | A Multicenter Phase II study to evaluate the clinical activity and the safety profile of everolimus (RAD001) in marginal zone B-cell lymphomas (MZL) |
| Investigator(s) responsible: | E. Zucca, A. Conconi |
| IELSG33 | A prospective observational study of newly diagnosed diffuse large B cell primary breast lymphomas treated with R-CHOP with or without radiotherapy |
| Investigator(s) responsible: | K. Ganjoo, G. Ryan, G. Martinelli |
| IELSG31 | A retrospective international study of primary extranodal follicular lymphoma |
| Investigator(s) responsible: | E. Zucca, B. Pro, Houston, M. Federico, A. Guillermo Lopez |
| IELSG29 | A retrospective study on primary bone marrow lymphoma |
| Investigator(s) responsible: | M. Rozman, A. Martínez-Pozo, C. Agostinelli, K. M. Hebeda, E. Matutes, M. Ponzoni, A. Ferreri, C. Campidelli, A. López-Guillermo, S. Pileri, E. Campo |
| IELSG28 | A retrospective international clinico-pathological study of primary extranodal marginal zone lymphoma of the lung (BALT-lymphoma) |
| Investigator(s) responsible: | G. Martinelli, P.L. Zinzani |
| IELSG27 | A Clinico-pathological phase II study with translational elements to investigate the possible infective causes of MALT lymphoma of the ocular adnexa with particular reference to Chlamydia species and the effects of treatment with tetracycline |
| Investigator(s) responsible: | Andrés J. M. Ferreri, Milan, Italy, John Radford, |
| IELSG26 | Clinico-pathologic study of primary mediastinal B-cell lymphoma |
| Investigator(s) responsible: | P.W.M. Johnson, E. Zucca, P.L. Zinzani, , M. Martelli, A. Lopez-Guillermo |
| IELSG25 | Phase II Study of VELCADE in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with prior systemic therapy |
| Investigator(s) responsible: | F. Cavalli |
| IELSG24 | A Phase I Study of Intrathecal Rituximab in Patients with Lymphomatous Meningitis |
| Investigator(s) responsible: | A. Conconi, A.J.M. Ferreri, F. Cavalli |
| IELSG23 | A retrospective evaluation of primary head and neck lymphoma |
| Investigator(s) responsible: | S. Cortelazzo, G. Gaidano, |
| IELSG22 | Gastric irradiation for MALT lymphoma: a retrospective study |
| Investigator(s) responsible: | A. Wirth, J. Seymour, M. Gospodarowicz, J. Yahalom, E. Zucca, |
| IELSG21 | Salvage therapy with Idarubicin in immunocompetent patients with relapsed or refractory primary central nervous system lymphomas |
| Investigator(s) responsible: | A.J.M. Ferreri |
| IELSG20 | Randomized phase II trial on primary chemotherapy with high-dose methotrexate, alone or associated with high-dose cytarabine, followed by response-and age-tailored radiotherapy for immunocompetent patients with newly diagnosed primary central nervous system lymphoma |
| Investigator(s) responsible: | A.J.M. Ferreri |
| IELSG19 | Multicenter randomized trial of chlorambucil versus chlorambucil plus rituximab versus rituximab alone in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) |
| Investigator(s) responsible: | E. Zucca, E. Montserrat, C. Thieblemont, G. Martinelli, P. Johnson |
| IELSG18 | Retrospective international survey on primary effusion lymphomas |
| Investigator(s) responsible: | A. Conconi, A. Carbone, D. Knowles, |
| IELSG17 | Multi-institutional retrospective analysis of intravascular lymphomatosis |
| Investigator(s) responsible: | A. Ferreri, M. Ponzoni, |
| IELSG16 | RT-PCR detection of the t(11;18) translocation as a predictor of outcome in extranodal marginal lymphoma of MALT type |
| Investigator(s) responsible: | F. Bertoni, E. Zucca, |
| IELSG15 | Retrospective evaluation of primary breast lymphoma |
| Investigator(s) responsible: | G. Martinelli, G. Ryan |
| IELSG14 | Retrospective evaluation of primary bone lymphoma |
| Investigator(s) responsible: | D. Christie, M. Gospodarowicz; B. Coiffier, G. Martinelli |
| IELSG13 | Prevalence of hepatitis C virus (HCV) infection among non-Hodgkin lymphoma (NHL) patients Feasibility study, involving a limited number of centers |
| Investigator(s) responsible: | E. Zucca, A. Conconi, |
| IELSG12 | Chromosome 11q amplification in primary extranodal diffuse large B-cell lymphomas |
| Investigator(s) responsible: | F. Bertoni, E. Finbarr, B Cotter, E. Zucca |
| IELSG11 | Retrospective evaluation of cutaneous B-cell lymphomas |
| Investigator(s) responsible: | S. Cortelazzo |
| IELSG10 | A phase II study of CHOP plus Rituximab, with intrathecal methotrexate followed by radiotherapy, in patients with primary testicular non-Hodgkin’s lymphoma |
| Investigator(s) responsible: | A. Sarris |
| IELSG9 | Retrospective evaluation of primary mediastinal large B-cell lymphomas |
| Investigator(s) responsible: | P. Zinzani, M. Martelli, M. Bertini |
| IELSG8 | Retrospective evaluation of primary intestinal lymphomas |
| Investigator(s) responsible: | S. Cortelazzo |
| IELSG7 | Retrospective evaluation of central nervous system lymphomas |
| Investigator(s) responsible: | J.Y. Blay, A. Ferreri, |
| IELSG6 | A phase II study to determine the clinical activity and safety of Rituximab (IDEC-C2B8) in marginal zone B-cell lymphomas (MZLs) |
| Investigator(s) responsible: | A. Conconi, C. Thieblemont |
| IELSG5 | Retrospective evaluation of primary testicular lymphomas |
| Investigator(s) responsible: | M. Gospodarowicz, T. Mughal, U. Vitolo |
| IELSG4 | Prospective randomized trial of chemotherapy vs chemotherapy plus irradiation in diffuse large-cell gastric lymphoma |
| Investigator(s) responsible: | G. Martinelli, |
| IELSG3 | Randomized trial of observation vs chlorambucil after anti-helicobacter therapy in low-grade gastric lymphoma |
| Investigator(s) responsible: | E. Zucca, E. Roggero |
| IELSG2 | Retrospective analysis of patients with primary localized diffuse large B-cell lymphoma of the stomach |
|
|
|
| IELSG1 | Retrospective evaluation of low-grade MALT lymphoma primarily arising at non-gastric sites |